Cost-effectiveness Analysis of Two Chemotherapy Regimens in the Treatment of Initially Diagnosed Multiple Myeloma / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the cost and effectiveness of two chemotherapy regimens in the treatment of initially di-agnosed multiple myeloma (MM). METHODS:63 patients who were newly diagnosed as MM without transplant chance in our hospital were analyzed retrospectively,and then divided into MPT group (alkeran+metacortandracin+thalidomide,41 cases) and VDT group (bortezomib +dexamethasone+thalidomide,22 cases) according to chemotherapy regimens. Clinical efficacy,survival time and ADR of 2 groups were observed,and cost-effectiveness analysis of them were conducted. RESULTS:The overall re-sponse rates of MPT group and VDT group were 63.4% and 77.3%,respectively(P=0.260);the complete response rate of them were 12.2% and 36.4%,with statistical difference(P=0.024). The progression free survival of MPT group and VDT group were (14.314±0.488)months and(18.557±0.848)months,with statistical significance(P<0.001);the overall survival of MPT group and VDT group were(33.536±1.143)months and(41.048±1.868)months,with statistical significance(P=0.007). Leukocytope-nia,nausea and vomit and peripheral neurotoxicity of VDT group were both higher than those of MPT group,with statistical signif-icance (P<0.05). The cost-effectiveness ratio of MPT group was 247.48,and that of VDT group was 2 922.77;the incremental cost-effectiveness ratio was 15 125.18. The results were consistent with the sensitivity test. CONCLUSIONS:Clinical efficacy and survival time of VDT regimen is better than that of MPT regimen,but MPT regimen is superior to VDT regimen in respect of cost-effectiveness analysis and the incidence of ADR. which will more suitable for the MM patients without transplant chance or goood economic conditions.